Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study.
about
Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophreniaSecond-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of lifeIdentifying the components of clinical vignettes describing Alzheimer's disease or other dementias: a scoping reviewTreatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database studyLong-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia.Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons.Health state utilities associated with attributes of treatments for hepatitis C.Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychoticsUtilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastasesIncorporating process utility into quality adjusted life years: a systematic review of empirical studies.Challenges to time trade-off utility assessment methods: when should you consider alternative approaches?Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain.Valuing Meta-Health Effects for Use in Economic Evaluations to Inform Reimbursement Decisions: A Review of the Evidence.Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension.
P2860
Q24597701-613CC75F-71F8-460B-9878-617D51A2ABCDQ26752965-9AF70787-4988-4E38-ACA0-7D5D1A593E4BQ26801830-D5ADBB2C-EA87-4735-A711-3EC78F1410E9Q33797431-97D739B3-EBE7-48B1-A32C-160C07F470E1Q36035382-FA4ED607-81CF-4BCD-AA5F-1AA9A42E2A65Q36183650-51552CF7-AE86-406F-9A1F-0638AE4CCB4AQ36285092-4539A873-C239-448F-BE69-D12DD44C11A1Q36467615-712C2C36-6536-4B1C-8AB8-07C43AC58F5DQ37163756-5654E49B-8152-400D-BEED-166795AD852BQ38114830-8203B245-DA88-426E-8493-C6F601FD3FD5Q38212030-8344F488-10BB-4E1D-9EB5-8CA09E98A521Q38649630-CCFAB779-E7D8-46D8-9665-0035826EF429Q38692993-848104AD-2C42-4B77-8667-EF0875BCBA3BQ39011868-CE0C5EE3-3C0C-463F-B1AE-C50522B9EAEDQ55286186-DD90E2AB-0D2B-45DD-A85E-7F868C5AB5A2
P2860
Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Health-related quality of life ...... renia: a time trade-off study.
@ast
Health-related quality of life ...... renia: a time trade-off study.
@en
type
label
Health-related quality of life ...... renia: a time trade-off study.
@ast
Health-related quality of life ...... renia: a time trade-off study.
@en
prefLabel
Health-related quality of life ...... renia: a time trade-off study.
@ast
Health-related quality of life ...... renia: a time trade-off study.
@en
P2093
P2860
P356
P1476
Health-related quality of life ...... renia: a time trade-off study.
@en
P2093
Andrew Dalton
Dell Kingsford Smith
Judy Hertel
Rudolf Schrover
P2860
P2888
P356
10.1186/1477-7525-10-35
P577
2012-04-02T00:00:00Z